Chimeric receptor with NKG2D specificity for use in cell therapy against cancer and infectious disease
AssigneesSt. Jude Children's Research Hospital, National University of Singapore
InventorsDario Campana, Yu-Hsiang Chang
Life of this patent
Estimating the term…
Abstract
The invention provides a chimeric receptor comprising NKG2D, DAP10 and CD3 zeta. Also disclosed is a composition comprising this chimeric receptor and methods for making and using it to enhance the cytotoxicity and antitumor capacity of NK cells. The invention also encompansses methods for use of NKG2D-DAP10-CD3 zeta polypeptides, vectors and cells in methods for treating cancer and other proliferative disorders, as well as infectious diseases.
Claims18
A method of producing an expanded population of natural killer (NK) cells, said method comprising:
- obtaining a peripheral blood sample,
- isolating from said peripheral blood sample a mixed population of mononuclear cells comprising NK cells and T cells,
- culturing said mixed population of cells under culture conditions resulting in the enhanced expansion of NK cells as compared to T cells,
- depleting the mixed population of residual T cells, and
- introducing into the NK cells nucleic acid encoding a chimeric receptor, the chimeric receptor comprising:
- i) an extracellular receptor domain, wherein said extracellular receptor domain comprises a peptide that binds one or more native ligands of Natural Killer Group 2 member D (NKG2D) receptor, wherein the extracellular receptor domain is at least 95% identical to an extracellular domain of a native human NKG2D receptor, and
- ii) one or more peptides that recruit downstream signaling effector molecules in response to binding of a native ligand by said extracellular receptor domain, wherein the one or more peptides comprise a CD3zeta cytoplasmic signaling domain, wherein the CD3zeta cytoplasmic signaling domain is at least 95% homologous to the amino acid sequence of SEQ ID NO:
- 10.
A method of producing a population of natural killer (NK) cells, said method comprising:
- obtaining a peripheral blood sample,
- isolating from said peripheral blood sample a mixed population of mononuclear cells comprising NK cells and T cells,
- culturing said mixed population of cells under culture conditions resulting in the enhanced expansion of NK cells as compared to T cells,
- removing T cells from said cell culture, and
- introducing into the NK cells a nucleic acid encoding a chimeric receptor comprising:
- i) an extracellular receptor domain, wherein said extracellular receptor domain comprises a peptide that binds one or more native ligands of NKG2D, wherein the extracellular receptor domain is at least 90% homologous to a NKG2D extracellular domain, wherein the NKG2D extracellular receptor domain comprises amino acids 81-215 of SEQ ID NO:
- 12, and
- ii) one or more peptides that recruit downstream signaling effector molecules in response to binding of a native ligand by said extracellular receptor domain, wherein the one or more peptides recruiting downstream signaling effector molecules comprises a CD3 zeta cytoplasmic signaling domain.
A method of producing a population of natural killer (NK) cells, said method comprising:
- isolating a mixed population of mononuclear cells comprising NK cells and T cells from a donor of a whole blood sample,
- culturing the mixed population of cells under culture conditions resulting in the enhanced expansion of NK cells as compared to T cells,
- removing T cells from said cell culture, and
- introducing into the NK cells at least two polypeptides that together encode a chimeric receptor,
- the first polypeptide encoding a extracellular receptor domain and a signaling domain, wherein said extracellular receptor domain comprises a peptide that binds one or more native ligands of NKG2D, wherein the first polypeptide encoding the extracellular receptor domain encodes an NKG2D extracellular domain,
- the second polypeptide encoding a stimulatory molecule, wherein the stimulatory molecule comprises the cytoplasmic signaling domain of CD3 zeta, wherein upon binding of one or more native ligands of NKG2D by the extracellular receptor domain, the NK cells exhibit one or more of enhanced cytotoxicity and anti-tumor capacity against target cells, triggered signal transduction, triggered secretion of cytokines and chemokines, increased target cell apoptosis, or sustained cytotoxicity against target cells.
Dependencies are inferred from the claim text.